The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic LeukaemiaAlessia Casolaro, Rachele Alzani, Gemma Texidó et al.|PLoS ONE|2013Cited by 34
Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myelomaClaudia Perrera, Barbara Valsasina, Maurizio Pulici et al.|Cancer Research|2017Cited by 1
Abstract A213: Potent anticancer activity <i>in vitro</i> and <i>in vivo</i> by NMS-E973, a novel synthetic inhibitor of HSP90Gianpaolo Fogliatto, Antonella Isacchi, Sergio Mantegani et al.|Molecular Cancer Therapeutics|2009Cited by 0
PLK1 expression in AML-NS8 cells and activity of PLK1 inhibitor NMS-937 <i>in vitro</i> and <i>in vivo</i>.Alessia Casolaro, Rachele Alzani, Josée Golay et al.|Figshare|2015Cited by 0